Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
AssigneeArne Forsgren AB
InventorsArne Forsgren, Kristian Riesbeck
Life of this patent
Estimating the term…
Abstract
The present invention relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present invention also provides peptides interacting with fibronectin, laminin and the complement system.
Claims23
A peptide consisting of Sequence ID No. 2, or a fragment, homologue, derivative, degenerate, a hydroxylation, sulphonation or glycosylation product, or other secondary processing product thereof that retains fibronectin binding properties.
A peptide consisting of Sequence ID No. 3, or a fragment, homologue, derivative, degenerate, a hydroxylation, sulphonation or glycosylation product, or other secondary processing product thereof that retains fibronectin binding properties.
A ligand comprising a fibronectin binding domain, said ligand consisting of an amino acid sequence selected from the group consisting of Sequence ID No. 2 and Sequence ID No. 3, or the ligand is a fragment, homologue, derivative, degenerate, a hydroxylation, sulphonation or glycosylation product, or other secondary processing product of the peptide of Sequence ID No. 2 or Sequence ID No. 3, wherein the ligand retains fibronectin binding properties.
A polypeptide or a polypeptide truncate comprising at least one of the conserved sequences of Sequence ID No. 2 or Sequence ID No. 3, or a fragment, homologue, derivative, degenerate, a hydroxylation, sulphonation or glycosylation product, or other secondary processing product thereof that retains the ability of binding fibronectin.
A vaccine composition comprising UspA1 and/or UspA2, protein MID, and one or more pharmaceutically acceptable adjuvants, vehicles, excipients, binders, carriers, or preservatives.
A method for the treatment or prophylaxis of an infection in an individual comprising administering a pharmaceutically effective amount of UspA1 and/or UspA2 and an effective amount of protein MID.
A vaccine composition comprising UspA1 and/or UspA2 and one or more pharmaceutically acceptable adjuvants, vehicles, excipients, binders, carriers, or preservatives.
Dependencies are inferred from the claim text.